Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults
Publication Date: April 1, 2019
Last Updated: March 14, 2022
Guideline Statements
Diagnosis
1. The clinician should engage in a diagnostic process to document symptoms and signs that characterize OAB and exclude other disorders that could be the cause of the patient's symptoms. The minimum requirements for this process are a careful history, physical exam, and urinalysis. (Clinical Principle, )
331578
2. In some patients, additional procedures and measures may be necessary to validate an OAB diagnosis, exclude other disorders and fully inform the treatment plan. At the clinician's discretion, a urine culture and/or post-void residual assessment may be performed and information from bladder diaries and/or symptom questionnaires may be obtained. (Clinical Principle, )
331578
3. Urodynamics, cystoscopy and diagnostic renal and bladder ultrasound should not be used in the initial workup of the uncomplicated patient. (Clinical Principle, )
331578
4. OAB is not a disease; it is a symptom complex that generally is not a life-threatening condition. After assessment has been performed to exclude conditions requiring treatment and counseling, no treatment is an acceptable choice made by some patients and caregivers. (Expert Opinion, )
331578
5. Clinicians should provide education to patients regarding normal lower urinary tract function, what is known about OAB, the benefits versus risks/burdens of the available treatment alternatives and the fact that acceptable symptom control may require trials of multiple therapeutic options before it is achieved. (Clinical Principle, )
331578
Treatment
First-Line Treatments: Behavioral Therapies
6. Clinicians should offer behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) as first line therapy to all patients with OAB. (Standard, B)
331578
7. Behavioral therapies may be combined with pharmacologic management. (Recommendation, C)
331578
Second-Line Treatments: Pharmacologic Management
8. Clinicians should offer oral anti-muscarinics or oral β3-adrenoceptor agonists as second-line therapy. (Standard, B)
331578
9. If an immediate release (IR) and an extended release (ER) formulation are available, then ER formulations should preferentially be prescribed over IR formulations because of lower rates of dry mouth. (Standard, B)
331578
10. Transdermal (TDS) oxybutynin (patch or gel) may be offered. (Recommendation, C)
331578
11. If a patient experiences inadequate symptom control and/or unacceptable adverse drug events with one anti-muscarinic medication, then a dose modification or a different anti-muscarinic medication or a β3-adrenoceptor agonist may be tried. (Clinical Principle, )
331578
12. Clinicians may consider combination therapy with an anti-muscarinic and β3-adrenoceptor agonist for patients refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists. (Option, B)
331578
13. Clinicians should not use anti-muscarinics in patients with narrow-angle glaucoma unless approved by the treating ophthalmologist and should use anti-muscarinics with extreme caution in patients with impaired gastric emptying or a history of urinary retention. (Clinical Principle, )
331578
14. Clinicians should manage constipation and dry mouth before abandoning effective anti-muscarinic therapy. Management may include bowel management, fluid management, dose modification or alternative anti-muscarinics. (Clinical Principle, )
331578
15. Clinicians must use caution in prescribing anti-muscarinics in patients who are using other medications with anti-cholinergic properties. (Expert Opinion , )
331578
16. Clinicians should use caution in prescribing anti-muscarinics or β3-adrenoceptor agonists in the frail OAB patient. (Clinical Principle, )
331578
17. Patients who are refractory to behavioral and pharmacologic therapy should be evaluated by an appropriate specialist if they desire additional therapy. (Expert Opinion , )
331578
Third-Line Treatments: PTNS and Neuromodulation
18. Clinicians may offer intradetrusor onabotulinumtoxinA (100U) as third-line treatment in the carefully-selected and thoroughly-counseled patient who has been refractory to first- and second-line OAB treatments. The patient must be able and willing to return for frequent post-void residual evaluation and able and willing to perform self-catheterization if necessary. (Standard, B)
331578
19. Clinicians may offer peripheral tibial nerve stimulation (PTNS) as third-line treatment in a carefully selected patient population. (Recommendation, C)
331578
20. Clinicians may offer sacral neuromodulation (SNS) as third-line treatment in a carefully selected patient population characterized by severe refractory OAB symptoms or patients who are not candidates for second-line therapy and are willing to undergo a surgical procedure. (Recommendation, C)
331578
21. Practitioners and patients should persist with new treatments for an adequate trial in order to determine whether the therapy is efficacious and tolerable. Combination therapeutic approaches should be assembled methodically, with the addition of new therapies occurring only when the relative efficacy of the preceding therapy is known. Therapies that do not demonstrate efficacy after an adequate trial should be ceased. (Expert Opinion , )
331578
Fourth-Line Treatments: Augmentation Cystoplasty and Urinary Diversion
22. In rare cases, augmentation cystoplasty or urinary diversion for severe, refractory, complicated OAB patients may be considered. (Expert Opinion , )
331578
Additional Treatments
23. Indwelling catheters (including transurethral, suprapubic, etc.) are not recommended as a management strategy for OAB because of the adverse risk/benefit balance except as a last resort in selected patients. (Expert Opinion , )
331578
Follow-Up
24. The clinician should offer follow up with the patient to assess compliance, efficacy, side effects and possible alternative treatments. (Expert Opinion , )
331578
Recommendation Grading
Overview
Title
Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults
Authoring Organizations
American Urological Association
Society of Urodynamics Female Pelvic Medicine & Urogenital Reconstruction
Publication Month/Year
April 1, 2019
Last Updated Month/Year
January 30, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder (OAB).
Inclusion Criteria
Female, Male, Adult, Older adult
Health Care Settings
Ambulatory, Hospital
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Diagnosis, Management, Treatment
Diseases/Conditions (MeSH)
D053201 - Urinary Bladder, Overactive
Keywords
Urinary Incontinence, overactive bladder